Paper Details

  1. Home
  2. Paper Details

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.

Author: , BowryC, BramhallS R, BrownP D, BuckelsJ A, RosemurgyA

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The survival rate for patients with unresectable pancreatic cancer is very low (less than 10% at one year and less than 5% at five years). New treatments, including conventional chemotherapy and molecular therapies, are being investigated. This study, the largest of its kind for pancreatic cancer, compared marimastat, a new type of drug, with gemcitabine, a standard chemotherapy agent.
Paper Details　
Original Abstract of the Article :
The prognosis for unresectable pancreatic cancer remains dismal (1-year survival rate, < 10%; 5-year survival rate, < 5%). Recent advances in conventional chemotherapy and novel molecular treatment strategies warrant investigation. This, the largest randomized study in pancreatic cancer performed to...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2001.19.15.3447

データ提供：米国国立医学図書館（NLM）

A comparative study of marimastat and gemcitabine in treating pancreatic cancer

This study compares the effectiveness of marimastat, a new type of cancer treatment, with gemcitabine, a standard chemotherapy drug, for treating unresectable pancreatic cancer. It's like comparing two different camel caravans traversing a treacherous desert, each employing unique strategies to navigate the challenges and reach their destination.

A challenging landscape: The fight against pancreatic cancer

Pancreatic cancer is a particularly aggressive and difficult-to-treat disease. This study investigates the potential of marimastat as a new weapon in the fight against this disease, seeking a more effective and tolerable treatment option. It's like discovering a new type of camel, better adapted to navigate the difficult terrain of pancreatic cancer.

Navigating the desert of treatment options: Comparing marimastat and gemcitabine

The study aims to determine whether marimastat offers a significant improvement over gemcitabine, which has been the standard treatment for pancreatic cancer. It's like comparing the effectiveness of different camel breeds, evaluating their strengths and weaknesses in navigating a treacherous landscape.

Dr.Camel's Conclusion

This study is a critical step in the fight against pancreatic cancer, like a cautious camel scout exploring new pathways through a treacherous desert. By comparing marimastat with gemcitabine, researchers are striving to find more effective and compassionate treatments, offering hope for a brighter future for patients battling this disease.

Date :
  1. Date Completed 2001-08-16
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

11481349

DOI: Digital Object Identifier

10.1200/JCO.2001.19.15.3447

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.